Cellectis S.A. (CLLS)

$3.81

+0.04 (+1.06%)
Rating:
Recommendation:
Neutral
Symbol CLLS
Price $3.81
Beta 2.280
Volume Avg. 0.14M
Market Cap 173.396M
Shares () -
52 Week Range 2.3-15.5
1y Target Est -
DCF Unlevered CLLS DCF ->
DCF Levered CLLS LDCF ->
ROE -56.12% Strong Sell
ROA -37.11% Strong Sell
Operating Margin -
Debt / Equity 65.80% Buy
P/E -
P/B 0.74 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest CLLS news


Dr. Andr Choulika
Healthcare
Biotechnology
NASDAQ Global Market

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.